Quote this publication Share Print

AVASTIN (bevacizumab), monoclonal antibody

ONCOLOGY - Focus
Opinions on drugs - Posted on Oct 12 2016

Reason for request

Re-assessment of the actual benefit and the improvement in actual benefit

In combination with fluoropyrimidine-based chemotherapy, no clinical benefit demonstrated in second-line treatment of metastatic colorectal cancer

 

  • In colorectal cancer, AVASTIN has Marketing Authorisation, in combination with fluoropyrimidine-based chemotherapy, as second-line treatment of metastatic colorectal cancer in adults.
  • In a new study, a low gain in overall survival (1.4 months) was observed, and in another study, a lack of gain was observed, with an increase in adverse events in both studies.
  • No comparison to an anti-EGFR drug in case of wild-type RAS tumour is available.

Clinical Benefit

Substantial

-


Clinical Added Value

no clinical added value

-


Contact Us

Évaluation des médicaments